Stock CGON CG ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CG Oncology, Inc.

Equities

CGON

US1569441009

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
34.9 USD -3.06% Intraday chart for CG Oncology, Inc. +1.78% 0.00%
Jun. 06 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CI
May. 24 Sector Update: Health Care Stocks Softer in Friday Afternoon Trading MT

Evolution of the average Target Price on CG Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e7b936827837b2d79417614b04223bf2.P6JGkCh_JSrByW-1I1mfGS_I1tAXGFkTx5uXj6qk9Ns.ecAcqGIvQBqgvlfQRQ7Nd0q4gJRhaWBL8K_W9cPovJxuyiPBcRlof7uqDA~e0eecff7fb9b67e2f61ca19b48dcd7c5

Analyst Recommendations on CG Oncology, Inc.

Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target MT
Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target MT
Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target MT
Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55 MT
HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.9 USD
Average target price
68.2 USD
Spread / Average Target
+95.42%
High Price Target
86 USD
Spread / Highest target
+146.42%
Low Price Target
50 USD
Spread / Lowest Target
+43.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CG Oncology, Inc.

Goldman Sachs
Cantor Fitzgerald
Morgan Stanley
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CGON Stock
  4. Consensus CG Oncology, Inc.